{
    "nctId": "NCT05764941",
    "briefTitle": "Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer",
    "officialTitle": "Real World Study of Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for Trastuzumab Resistant HER2-positive Metastatic Breast Cancer: a Multicenter, Retrospective Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female and 18-80 years old;\n2. The patient was diagnosed as HER2-positive breast cancer by histopathology (HER2 positive (IHC +++ or IHC++ but FISH/CISH+ ));\n3. All patients have previously received \u2264 2 lines chemotherapy for metastatic breast cancer;\n4. Patients received inetetamab combined with pyrotinib and vinorelbine after trastuzumab failure;\n5. According to RECIST 1.1, patients with at least one target lesion or simple bone metastasis can be evaluated;\n6. ECOG score of physical status was less than 2, and the expected survival time was not less than 3 months;\n7. Complete and traceable medical data.\n\nExclusion Criteria:\n\n1. Incomplete medical data;\n2. The investigator believes that the patient is not suitable to enter this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}